Company RxElite, Inc.

Equities

RXEI

US78347X1054

Pharmaceuticals

Market Closed - OTC Markets 03:17:56 2023-04-03 pm EDT 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for RxElite, Inc. -.--% -.--%

Business Summary

RxElite, Inc. (RxElite) develops and markets generic prescription drug products in specialty generic markets. RxElite's markets and pipeline products are in specialty markets. These markets include specialty products in the areas of anesthesia gases, sterile liquid dose products, which includes ophthalmic products, sterile inhalation respiratory products and injectable, drugs and active pharmaceutical ingredients (APIs). The Company's customers include hospitals and hospital group purchasing organizations, national and regional wholesalers, direct retail pharmacy stocking chains, homecare companies, and outpatient surgery centers and ambulatory care clinics. In January 2008, RxElite acquired FineTech Laboratories, Ltd, which manufactures APIs in its facility in Haifa, Israel. In January 2009, RXElite announced the sale of all the issued and outstanding capital stock of RxElite Holdings Inc. (Holdings), its wholly owned United States subsidiary, to Piramal Healthcare Limited.

Number of employees: 47

Sales per Business

USD in Million2007Weight Delta
Pharmaceutical Preparations
100.0 %
3 100.0 % -

Sales per region

USD in Million2007Weight Delta
United States
100.0 %
3 100.0 % -

Managers

Managers TitleAgeSince
Chief Executive Officer 52 07-07-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 119,705,157 81,600,000 ( 68.17 %) 0 68.17 %

Company contact information

RxElite, Inc.

1404 North Main Street Suite 100

83642, Meridian

+

address RxElite, Inc.(RXEI)